Navigation Links
Researcher of the University of Navarra discovered potential antidepressant compounds
Date:2/20/2008

This release is also available in Spanish.

Luis Berrade, a researcher with the Drug R&D Unit of the University of Navarra, has discovered new compounds with the potential for anti-depressant activity. All told, the chemist of the School of Sciences synthesized 51 compounds whose biological characteristics were evaluated by two of the most prestigious groups in this area: the Mediterranean Institute of Neurobiology, located in Italy, and the Department of Pharmacology of the University of Oslo.

The results obtained formed part of his doctoral dissertation, entitled Design, synthesis and preliminary biological evaluation of new derivatives of benzo[b]-thiophene in the Search for Agents for a New Anti-Depressant Therapy.

As the researcher explained, the new molecules which he designed affect two brain targets which are considered to be keys in the development of processes of depression. One of these is the serotonin transporter, whose reuptake reduction has already been shown to improve mood; the other is the serotoninergic receptor 5-HT7, a therapeutic target for serotonin whose modulation can provoke anti-depressant effects.

Trials in vivo

In order to study these two key targets, Luis Berrade developed chemical structures via the fusion of two similar chemical compounds: the benzo[b]-thiophene ring and arilamine. Following this, he compared the new compounds with a drug currently on the market, Fluoxetine. As a result of this research, he explained, we discovered that nine of these compounds demonstrated greater affinity, in this sense, than the commercial drug. As a consequence of this discovery, in January in vivo trials were begun in order to test their anti-depressant activity in mice.

This study, one of the first in the world in this specialty, was undertaken in collaboration with the Department of Pharmacology of the University of Navarra. Among its objectives was discovering whether these new compounds could reduce the minimum time required for anti-depressant drugs to ameliorate the symptoms of the disease: Currently, the time for an antidepressant to take effect is from three to six weeks, and this is an important factor in patient refusal to continue with these treatments; as a result it is very important to shorten the time required for the positive effects to appear.


'/>"/>

Contact: Oihane Lakar
oihane@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. Bipolar disorder relapses halved by Melbourne researchers
6. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
7. High and mighty: first common height gene identified by researchers behind obesity gene finding
8. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
9. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
10. Researchers develop long-lasting growth hormone
11. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/10/2017)... COUNTY, Calif. , Oct. 10, 2017  NDS received FDA ... Mobile  — a medical-grade battery-powered display stand specifically designed for endoscopy ... to transform technology into a clinical solution to support the improvement ... Innovative Design ... ZeroWire Mobile Wireless Solution ...
(Date:10/5/2017)... ROSEMONT, Ill. , Oct. 5, 2017 /PRNewswire-USNewswire/ ... American Association of Oral and Maxillofacial Surgeons (AAOMS) ... than opioids – to be used as a ... post-surgical pain. ... relationship, the AAOMS White Paper "Opioid Prescribing: Acute ...
Breaking Medicine Technology: